Mitchell Hymowitz

Partner at The Column Group

Mitchell Hymowitz is a crisis management financial expert with a strong background in serving as an Interim CFO to navigate complex investment deals and financial challenges.

With a focus on guiding C teams, diagnosing systems, and creating financial forecasting models, Mitchell is sought after by companies looking to improve their financial strategies and overcome obstacles.

His expertise extends to working with entrepreneurs, start-up investors, attorneys, CPAs, and VCs in areas such as start-up financings, M&A, investment due diligence, and financial restructuring.

Specializing in industries like pharmaceuticals, SaaS, consumer goods, Mitchell brings extensive experience from working with numerous clients and handling deals totaling over $500 million.

Educationally, Mitchell holds an MBA in Strategic Planning from NYU Stern School of Business and a BA in Accounting & Computer Science from Rutgers University.

With a history of leadership roles in various organizations, including Brave Health, Data Skrive, Theo Chocolate, and more, Mitchell's expertise shines through his consulting CFO and business modeling ventures.

Experience

Partner at The Column Group (September 2021 - Present)

- Vice President, Protein Sciences at Genentech (May 2017 - August 2021) - Vice President, Protein Chemistry & Structural Biology at Genentech (November 2016 - May 2017) - Senior Director of Protein Chemistry & Structural Biology at Genentech (November 2014 - November 2016) - Director of Structural Biology at Genentech (2012 - November 2014) - Associate Director at Genentech (2010 - 2012) - Senior Scientist, Scientist, Post Doctoral Fellow at Genentech (January 1999 - 2010)

Education

- Doctor of Philosophy (Ph.D.) in Biophysics, University of California, San Francisco (1992 - 1998) - Bachelor of Arts (B.A.) in Chemistry, Swarthmore College (1988 - 1992)